Based on the outstanding expertise and rich experience, Creative Biolabs has specially developed a system approach of TCR generation and optimization for TCR development.
T cell mediated cellular immunity plays a pivotal role in tumor rejection. Through their surface T cell receptor (TCR), T cells recognize short 9-10mer peptide epitope presented by major histocompatibility complex (MHC) class I proteins on the surface of cells. Enhancing the numbers and activity of tumor-infiltrating lymphocytes (TILs), which are mostly composed of T lymphocytes, is among the early approaches that immunologists and oncologists tested to treat cancer. TCRs have been intensively studied for anti-tumor immunotherapy. The idea that targeting single epitopes derived from cancer-specific or cancer-related antigens is sufficient to treat cancer has fueled research efforts to identify suitable epitopes and has opened up many new routes for developing novel anti-cancer immunotherapy agents. Therefore, TCRs with their own advantages become significant products for cancer therapy.
Preclinical in vivo therapeutic efficacy test of TCR-T cells in animal models provides valuable information for their late clinical application. Particularly, efficacy of TCRs is a key factor for selection in clinical later stage. With years of experience in preclinical in vivo research and project management, Creative Biolabs is able to provide therapeutic efficacy test service for a proof-of-concept or therapeutic efficacy validation by utilizing appropriate animal models, designing comprehensive research practices and handling high-quality in vivo studies. We are capable of conducting many tests to evaluate the therapeutic efficacy of the CAR-T cell therapy, such as in vivo imaging, clinical observation.
Creative Biolabs has the capability to enable you to free up your time for core work and project. Our service can be designed to meet your special needs if you have any requirements. If you are interested in our service, please contact us by E-mail and our team will get back to you as soon as possible.
Demin Li, et al. Engineering chimeric human and mouse major histocompatibility complex (MHC) class I tetramers for the production of T-cell receptor (TCR) mimic antibodies. Plos One, 4 (2017): 1-16.
For any technical issues or products/services related questions, please leave your contacts as below, and our team will contact you at earliest convenience to let you know how we can be involved in your projects.
Nanoparticle Tiny Tech for Programming T Cells: A novel technology to increase the efficiency and value of your CAR-T therapy project.LEARN MORE
End-to-end CAR Hybrid TCR (CHyT)-T Cell Therapy Development Services: A novel solution to engineer T cell to be a promising cellular therapy with the complete TCR without HLA dependence.LEARN MORE
TRAC-CAR-T Cell Development with CRISPR/Cas9 Technology: A novel technology to build more powerful CAR-T cells.LEARN MORE